OncoAlert Round Up for September 15-21, 2023

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer

OncoAlert Round Up for September 1-7, 2023

Part 6: Which different PARP inhibitors are available

Part 7: Similarities and Differences

Part 8: How PARP inhibitors are being used now

Part 9: What PARP inhibitors mean for the future and what to look out for

Asia-Pacific Oncology Alliance

Cancer control initiatives at the National Cancer Center Korea

Models of survivorship for breast cancer patients in Korea

SEABCS 2023: Supporting breast cancer patients in South East Asia

Global Focus on Cancer